scispace - formally typeset
J

Josef Höfler

Researcher at Technische Universität München

Publications -  5
Citations -  412

Josef Höfler is an academic researcher from Technische Universität München. The author has contributed to research in topics: Pollen & Internal medicine. The author has an hindex of 4, co-authored 4 publications receiving 345 citations.

Papers
More filters
Journal ArticleDOI

Chilling outweighs photoperiod in preventing precocious spring development.

TL;DR: The results reveal that increased winter temperatures might impact forest ecosystems more than formerly assumed and indicate that temperature requirements and successional strategy are linked, with climax species having higher chilling and forcing requirements than pioneer species.
Journal ArticleDOI

Nutrient status: a missing factor in phenological and pollen research?

TL;DR: In this paper, the effects of air temperature and 11 nutrients on spring phenology of Betula pendula Roth (birch) along an urban-rural gradient in Munich, Germany, during the years 2010/2011 were examined.
Journal ArticleDOI

Association of tree and plot characteristics with microhabitat formation in European beech and Douglas-fir forests

TL;DR: In this article, the authors investigated the factors that trigger the formation of microhabitats at both the individual tree and aggregated plot level, and whether the co-occurrence of micro-habitat types differs between managed and unmanaged forests.

Nutrient status : a missing factor in phenological and pollen research? Journal of Experimental Botany

TL;DR: The results of this study suggested an influence of nutritional status on both phenology and pollen production and the interaction of urbanization and climate change should be considered in the assessment of the impact of global warming on ecosystems and human health.
Journal ArticleDOI

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis

TL;DR: In this paper , a randomized clinical trial evaluated matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizer in patients with relapsing-remitting multiple sclerosis.